Finch featured in New York Times article on FMT and drug development

Over the past decade, tens of thousands of Americans with C. diff have been cured through fecal transplants, often with a single dose that can bring patients back from the brink of death. The treatment has more than an 80 percent success rate, according to several studies, and many patients feel better within hours of receiving the procedure, which is usually administered through colonoscopy or capsules containing desiccated fecal matter.

Read more

Leveraging Finch’s machine learning expertise in C. diff. and beyond

CEO Mark Smith describes the vast potential of the microbiome and Finch’s therapeutic platforms:

“We think the microbiome is really fundamental to many aspects of who we are, how our immune systems function, how we regulate our metabolism and how we think and feel,’ says Smith, who predicts ‘broad potential across a number of therapeutic areas.”

Microbiotal reverse-engineering: How Finch is moving from fecal microbiota transplant to oral therapy

Microbiotal reverse-engineering: How Finch is moving from fecal microbiota transplant to oral therapy

Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema.

Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

Back when Mark Smith was working on his PhD at MIT about 6 years ago, his girlfriend’s cousin was infected with C.diff. After 7 reoccurrences following treatment with vancomycin, though, the cousin finally beat it by getting a fecal transplant, with his roommate as the donor.